Jun Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jun Qin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Lilin Ma
Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226000, PR China
2 shared publicationsXiaofei Zhi
Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226000, PR China
2 shared publicationsFeiran Wang
Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People's Republic of China
1 shared publication- Jiaxuan Zhang
Department of Emergency Surgery, The Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226000, PR China
1 shared publication Jing Ke
Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People's Republic of China
1 shared publicationJinqiu Tao
Department of General Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210029, China
1 shared publication
Latest Publications
- 1 October 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 505 (2) , 346-352
Hsa_circRNA_103809 regulated the cell proliferation and migration in colorectal cancer via miR-532–3p / FOXO4 axis
- 1 October 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 505 (2) , 346-352
Hsa_circRNA_103809 regulated the cell proliferation and migration in colorectal cancer via miR-532–3p / FOXO4 axis
- Open Access
- 29 December 2016
- Published by Springer Nature in Cell Death & Disease
- Vol. 7 (12) , e2569
Silencing speckle-type POZ protein by promoter hypermethylation decreases cell apoptosis through upregulating Hedgehog signaling pathway in colorectal cancer
Epigenetic silencing of tumor suppressors contributes to the development and progression of colorectal cancer (CRC). We recently found that speckle-type POZ protein (SPOP) was significantly downregulated and the inactivation of SPOP promoted metastasis in CRC. This study aimed to clarify its epigenetic alteration, molecular mechanisms and clinical significance in CRC. Our results revealed that the core region of SPOP promoter was hypermethylated in CRC tissues and its methylation was correlated with poor survival. Transcription factor RXRA had a vital role in the regulation of SPOP gene. The data indicated that DNA methylation at −167 bp of the SPOP gene altered the binding affinity between transcription factor RXRA and SPOP promoter. Moreover, SPOP was found to associate with Gli2 and promoted its ubiquitination and degradation in CRC. Consequently, the expression level of Hh/Gli2 pathway-related apoptotic protein Bcl-2 was decreased and the function of resisting cell death was inhibited in CRC. It suggests that methylation status of SPOP promoter can be used as a novel epigenetic biomarker and a therapeutic target in CRC.
- 29 December 2016
- Published by Springer Nature in Cell Death & Disease
- Vol. 7 (12) , e2569
Open AccessSilencing speckle-type POZ protein by promoter hypermethylation decreases cell apoptosis through upregulating Hedgehog signaling pathway in colorectal cancer
Epigenetic silencing of tumor suppressors contributes to the development and progression of colorectal cancer (CRC). We recently found that speckle-type POZ protein (SPOP) was significantly downregulated and the inactivation of SPOP promoted metastasis in CRC. This study aimed to clarify its epigenetic alteration, molecular mechanisms and clinical significance in CRC. Our results revealed that the core region of SPOP promoter was hypermethylated in CRC tissues and its methylation was correlated with poor survival. Transcription factor RXRA had a vital role in the regulation of SPOP gene. The data indicated that DNA methylation at −167 bp of the SPOP gene altered the binding affinity between transcription factor RXRA and SPOP promoter. Moreover, SPOP was found to associate with Gli2 and promoted its ubiquitination and degradation in CRC. Consequently, the expression level of Hh/Gli2 pathway-related apoptotic protein Bcl-2 was decreased and the function of resisting cell death was inhibited in CRC. It suggests that methylation status of SPOP promoter can be used as a novel epigenetic biomarker and a therapeutic target in CRC.
- Open Access
- 1 December 2015
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 8, 3639-3648
Downregulation of microRNA-132 by DNA hypermethylation is associated with cell invasion in colorectal cancer
MicroRNAs (miRNAs) are small, noncoding RNAs that are involved in many biological processes, and aberrant regulation of miRNAs is always associated with cancer progression and development. Abnormal expression of miRNA-132 (miR-132) has been found in some types of cancer, but the effects and potential mechanisms of miR-132 in colorectal cancer (CRC) have not been explored to date. In this study, quantitative real-time polymerase chain reaction was used to investigate the level of miR-132 in CRC tissues and their paired adjacent normal tissues. Bioinformatics analysis indicated that the mechanism underlying the tumor suppressor role of miR-132 in CRC cells may play a role in tumor suppression by targeting paxillin. Furthermore, methylation-specific polymerase chain reaction was performed to evaluate the methylation status of the miR-132 regulatory region. A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, was used to activate the expression of miR-132 in CRC cells in vitro. Downregulation of miR-132 may occur as a result of hypermethylation and implies a poor prognosis in CRC; therefore, triggering miR-132 reexpression by using DNA methyltransferase inhibitors may be a potential molecular therapeutic target for CRC.
- 1 December 2015
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 8, 3639-3648
Open AccessDownregulation of microRNA-132 by DNA hypermethylation is associated with cell invasion in colorectal cancer
MicroRNAs (miRNAs) are small, noncoding RNAs that are involved in many biological processes, and aberrant regulation of miRNAs is always associated with cancer progression and development. Abnormal expression of miRNA-132 (miR-132) has been found in some types of cancer, but the effects and potential mechanisms of miR-132 in colorectal cancer (CRC) have not been explored to date. In this study, quantitative real-time polymerase chain reaction was used to investigate the level of miR-132 in CRC tissues and their paired adjacent normal tissues. Bioinformatics analysis indicated that the mechanism underlying the tumor suppressor role of miR-132 in CRC cells may play a role in tumor suppression by targeting paxillin. Furthermore, methylation-specific polymerase chain reaction was performed to evaluate the methylation status of the miR-132 regulatory region. A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, was used to activate the expression of miR-132 in CRC cells in vitro. Downregulation of miR-132 may occur as a result of hypermethylation and implies a poor prognosis in CRC; therefore, triggering miR-132 reexpression by using DNA methyltransferase inhibitors may be a potential molecular therapeutic target for CRC.